Abstract
The acute leukemias are a heterogeneous group of neoplasms affecting uncommitted or partially committed hematopoietic stem cells. The origin of the malignant neoplasm is almost invariably within the marrow. Replacement of the marrow pulp or the repression of normal hematopoietic cells results in variable degrees of anemia, neutropenia, and thrombocytopenia.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Gralnick HR, Sultan C. Acute promyelocytic leukemia, hemorrhagic manifestations and morphologic criteria. Br J Haematol. 1975;29:373.
Sultan C, Deregnaucourt J, Ko YW, et al. Distribution of 250 cases of acute myeloid leukemia(AML) according to FAB classification and response to therapy. Br J Haematol. 1981;47:545.
Manohoran A, Horsley R, Ptiney WR. The reticulin content of bone marrow in acute leukemia in adults. Br J Haematol. 1979;43:185.
Islam A. Proposal for a classification of acute myeloid leukemia based on plastic embedded bone marrow biopsy section. Leuk Res. 1993;17:421.
Neiman RS, Barcos M, Berard C, et al. Granulocytic sarcoma. Cancer. 1981;48:1426.
Bennett JM, Catovsky D, Daniel MT, et al. Proposal for classification of acute leukemias. Br J Haematol. 1976;33:451.
Bennet JM, Reed CE. Acute leukemia cytochemical implications. Blood Cells. 1975;1:101.
Jaffe ES, Harris NL, Stein H,Vardiman JW, editors. World Health Organization classification of tumors. In: Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
Swerdlow SH, Compo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998.
Heerema NA, Sather Ge J, et al. Cytogenetic studies of infant acute lymphoblastic leıkemia: poor prognosis of infants with t(4;11)- a report of Children’s Cancer Group. Leukemia. 1999;13:679.
Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211.
Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: result of trial ALL BFM 90.German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310.
Flandrin G, Brouet JC, Daniel MT, et al. Acute leukemia with Burkitt’s tumor cell. Blood. 1975;45:183.
Berger R, Bernheim A, Brouet JC, et al. t(8;14) translocation in a Burkitt’s type of lymphoblastic leukemia(L3). Br J Haematol. 1979;43:81.
Pui CH, Behm FG, Crist WN. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 1993;82:343.
Michiels JJ, Adriiaansen HJ, Hagemeijer A, et al. TdT positive B cell acute lymphoblastic leukemia(B-ALL). Br J Haematol. 1988;68:423.
Bennett JM, Catovsky D, Daniel MT, et al. The morphologic classification of acute lymphoblastic leukemia: the morphologic classification of acute lymphoblastic leukemia: concordance among observers and clinical correlations. Br J Haematol. 1981;47:553.
Childs CC, Stass SA, Bennett JM. The morphologic classification of acute lymphoblastic leukemiain childhood: observation on concordance utilizing a simple scoring system. Am J Clin Pathol. 1986;86:503.
Miller DR, Krailo M, Bayer WA, et al. Prognostic implication of blast cell morphology in childhood acute lymphoblastic leukemia: a report from children’s cancer study group. Cancer Treat Rep. 1985;69:1211.
Tricot G, Broeckaert-Van Orshoren A, Van Hoof A, et al. Sudan Black B positivity in acute lymphoblastic leukemia. Br J Haematol. 1982;51:615.
Lillyman JS, Hann IM, Stevens RF, et al. Blast vacuoles in childhood acute lymphoblastic leukemia. Br J Haematol. 1988;70:183.
Bain B, Catovsky D. Current concerns in hematology. 2. Classification of acute leukemia. J Clin Pathol. 1990;43:882.
Catovsky D, Cherchi M, Graves MF, et al. Acid phosphatase reaction in acute lymphoblastic leukemia. Lancet. 1978;1:749.
De Olivera MP, Grgory C, Matutes E, et al. Cytochemical profile of megakaryoblastic leukemia: a study with cytochemical method, monoclonal antibodies and ultrastructural cytochemistry. J Clin Pathol. 1987;40:663.
De Olivera MP, Matutes E, Catovsky D. The cytochemistry, membrane markers and ultrastructure of megakaryoblastic (M7) and erythro (M6) leukemias. In: Scott CS, Harwood E, editors. Leukemia cytochemistry: principles and practice. Chichester: Wiley; 1989, p. 137.
Cordell JL, Fallini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immunocomplexes of alkaline phosphatase and monoclonal alkaline phosphatase(APAAP complex). J Histochem Cytochem. 1984;32:219.
Olsen RJ, Chang CC, Herrick JL, et al. Acute leukemia immunohistochemistry: a systemic diagnostic approach. Arch Pathol Lab. 2008;132:462.
Faderi S, Jeha S, Kantarjiyan HM. The biology and therapy of adult lymphoblastic leukemia. Cancer. 2003;98:1337.
Manchini M, Scapatticci D, Cimino G, et al. A comprehensive genetic classification of adult lymphoblastic leukemia (ALL): analysis of the GIEMMA 0496 protocol. Blood. 2005;105:3434.
Pui CH, Evans WE. Acute lymphoblastic leukemia. N Eng J Med. 1998;339:605.
Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood. 1996;87:1211.
Crist W, Caroll A, Shuster J, et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group Study. Blood. 1990;76:489.
Hoberman AL, Westbrook CA, Davey FR, et al. Molecular detection of Philadelphia (Ph1) chromosome in acute lymphoblastic leukemia (ALL): clinical, cytogenetic and immunologic correlations in a CALGB Study. Blood. 1989;74:52a.
Bloomfield CD, Goldman AI, Alimena G, et al. Chromosomal abnormalities identify high risk and low risk patients with acute lymphoblastic leukemia. Blood. 1986;67:415.
Champlin G, Gale RP. Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood. 1989;73:2051.
Altman AJ. Clinical features and biological implications of acute mixed lineage (Hybrid) leukemias. Am J Pediatr Hematol Oncol. 1990;12:123.
Cobaleda C, Gutierez-Cianca N, Perez-Losada J, et al. A primitive hematopietic cell is the target for the leukemic transformation in human Philadelphia positive acute lymphoblastic leukemia. Blood. 2000;95:1007.
Morley A, Higgs D. Abnormal differentiation of leukemic cells in-vitro. Cancer. 1974;33:716.
Drexler HG, Thiel E, Ludwig WD. Acute myeloid leukemias expressing lymphoid associated antigens: diagnostic incidence and prognostic significance. Leukemia. 1993;7:489.
Jensen MK, Killman SA. Additional incidence for chromosomal abnormalities in the erythroid precursors in acute leukemia. Acta Med Scand. 1971;189:97.
Ackerman GA. Microscopic and histochemical studies on the Auer bodies in leukemic cells. Blood. 1950;7:1230.
Bainon DF, Friedlander LM, Shohet SB. Abnormalites in granule formation in acute myelogeneous leukemia. Blood. 1977;49:639.
Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for classification of acute myeloid leukemia. Ann Intern Med. 1985;103:626.
Goasguen JE, Bennett JM, Cox C, et al. Prognostic implication and characterization of blast cell population in myelodysplastic syndrome. Leuk Res. 1991;15:1159.
Cheson BD, Cassileth A, Head DR, et al. Report of National Cancer Institute Sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1950;8:813.
Mufti JG, Bennett JM, Goasguen JE, et al. Diagnosis and classification of myelodysplastic syndrome: international working group on morphology of myelodysplastic syndrome (IWGM.MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Hematologica. 2008;93:1712.
Arber DA, Stein AS, Carter NH, et al. Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119:672.
Arber DA, Brunning RD, LeBeau MM, et al. Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow SH, Compo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 110–23.
Wardiman JW, Arber DA, Brunning D, et al. Therapy related myeloid neoplasms. In: Swerdlow SH, Compo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 127–9.
Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukemia with myelodysplasia related changes: In: Swerdlow SH, Compo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 124–9.
Baumann I, Neimeyer CM, Brunning RD, et al. Myeloid proliferations related to Down Syndrome. In: Swerdlow SH, Compo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 142–4.
Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukemia, not otherwise specified. In: Swerdlow SH, Compo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 130–9.
Wardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937.
Bennett JM, Castoldi D, Catovsky D, et al. Recommended methods for cytological procedures in hematology. Clin Lab Hematol. 1985;7:55.
Goasguen JE, Bennett JM. Classification of acute leukemia. Clin Lab Med. 1990;10:661.
Van Wering ER, Brederoo P, Staalduien GJ, et al. Contribution of electron microscopy to the classification of minimally differentiated acute leukemia in children. Recent Results Cancer Res. 1993;13:177.
Van Wering ER, Brederoo P, Van Dijk-de-Leeuw JHS. Electron microscopy: a contribution to further classification of acute unclassifiable childhood leukemia. Blut. 1990;60:291.
Orazi A. Histopathology in the diagnosis and classification ao acute myeloid leukemia, myelodysplastic syndrome and myelodysplastic/myeloproliferative diseases. Pathobiology. 2007;74:97.
Downing JR. The AML1-ETO chimeric transcription in acute myeloid leukemia biology and clinical significance. Br J Haematol. 1999;106:296.
Second International Workshop on Chromosomes in Leukemia. Cytogenetic, morphologic and clinical correlations in acute nonlymphocytic leukemia with t(8;21). Cancer Genet Cytogenet. 1980;2:99.
Kita K, Nakase K, et al. Phenotypical characteristics of acute myelocytic leukemi associated with the t(8;21)(q22;q22) chromosomal abnormality frequent expression of immature B cell antigen CD19 together with stem cell antign CD34. Blood. 1992;80:470.
Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC-AML10 trial. The Medical Research Council Adult and Children’s Leukemia Working Parties. Blood. 1998;92:2322.
Paschka P, Marrucci G, Ruppert AS, et al. Adverse prognostic signifcance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904.
Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic inpact of c-KIT, FLR3 and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20:965.
Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol. 2008;35:410.
Cartrer M, Kalwinsky DR, Dahl GV, et al. Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features. Leukemia. 1989;4:298.
Chang KS, Stass SA, Chu DT, et al. Characterization of a fusion cDNA(RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia. Mol Cell Biol. 1992;12:800.
Chang KS, Lu J, Wang G, et al. The t(15;15) breakpoint in acute promyelocytic leukemia cluster within two different sites on the myl gene. Targets for the detection of minimal residual disease by the polymerase chain reaction. Blood. 1992;79:554.
De The H, Lavau C, Marchio A, et al. The PML-RAR fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675.
Castaigne S, Chomienne C, Daniel MT, et al. All trans retinoic acid as a differentiating therapy for acute promyelocytic leukemia. Blood. 1990;76:1704.
Warrell RP, Frankel SR, Miller Jr WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385.
Bennett JM, Catovsky D, Daniel MT, et al. A variant form of hypergranular acute promyelocytic leukemia(M3) French-American-British (FAB) classification. Br J Haematol. 1980;44:169.
San Miguel JF, Gonzales M, Canizo MC, et al. Surface marker analysis in acute myeloid leukemia and correlation with FAB classification. Br J Haematol. 1986;64:547.
Scott RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990;8:1913.
Roveli A, Biondi A, Rajnoldi AC, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol. 1992;10:1413.
Kussick SJ, Stirewalt DL, Yi HS, et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia. 2004;18:1591.
Zelent A, Guidez F, Melnick A, et al. Translocation of the RAR-alpha gene in acute promyelocytic leukemia. Oncogene. 2001;20:7186.
Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167.
Shigesada K, van de Sluis B, Liu PP. Mechanism of leukomogenesis by the inv (16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene. 2004;23:4297.
Mariton P, Keating M, Kantarjian H, et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia. 1995;9:965.
Mrozek K, Heinonen K, de la Chapelle A, et al. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17.
Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukemia. Br J Heamatol. 2000;109:13.
Bain BJ, Moorman AV, Johansson B, et al. Myelodysplastic syndromes associated with 11q23 abnormalities. Leukemia. 1998;12:834.
Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overal survival in adult patients with de novo acute myeloid leukemia results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325.
Forestier E, Heim S, Blennow E, et al. Cytogenetic abnormalities in childhood acute myeloid leukemia: a Nordic series comprising a children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol. 2003;121:566.
Sorensen PH, Chen CS, Smith FO, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin İnvest. 1994;93:429.
Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111:4329.
Slovak ML, Gundacker H, Bloomfield CD, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasized the need for a prospective multicenter initiative for rare poor prognosis myeloid malignancies. Leukemia. 2006;20:1295.
Oyarzo MP, Lin P, Glassman A, et al. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and high frequency of FLT3 gene mutations. Am J Clin Pathol. 2004;122:348.
Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a southwest oncology group/eastern cooperative oncology group study. Blood. 2000;96:4075.
Grigg AP, Gascoyne RD, Phillips GL, et al. Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. Br J Haematol. 1993;83:158.
Jenkins RB, Tefferi A, Solberg LA, et al. Acute leukemia with abnormal thrombopoiesis and invertions of chromosome 3. Cancer Genet Cytogenet. 1989;39:167.
Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy. A United Kingdom Cancer Cytogenetic Group study. Br J Haematol. 1995;91:490.
Reiter E, Greinix H, Rabitsch W, et al. Low curative potential of bone marrow transplantation for highly aggressive acute myelogeneous leukemia with invertion inv(3)(q21;q26) or homologous translocation t(3;3)(q21;q26). Ann Hematol. 2000;79:374.
Hama A, Yagasaki H, Takahashi Y, et al. Acute megakaryoblastic leukemia (AMKL) in children in comparison of AKML with and without Down syndrome. Br J Haematol. 2008;140:552.
Athale UH, Kaste SC, Razzouk BL, et al. Skeletal manifestations of pediatric acute magakaryoblastic leukemia. J Pediatr Heamatol Oncol. 2002;24:561.
Duchayne E, Fenneteau O, Pages MP, et al. Acute megakaryoblastic leukemia: a national clinical and biological study of 53 adult and childhood cases by the Groupu Francais d’Hematologie Cellulaire (GFHC). Leuk Lymphoma. 2003;44:49.
Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene- expression changes in acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically polarized molecular classification? Blood. 2007;109:431.
Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/1836 mutations are associated with poor disease free survival and a distinct gene expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lackinf FLT3 internal tandem duplications. Blood. 2008;111:1552.
Brown P, Mclntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007;110:979.
Fallini B, Mecucci C, Saglio G, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Hematologica. 2008;93:439.
Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin(MPM1) predicts favurable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740.
Leroy H, Roumier C, Huyghe P, et al. CEBPA point mutations in hematological malignancies. Leukemia. 2005;19:329.
Head DR. Revised classification of acute myeloid leukemia. Leukemia. 1996;10:1826.
Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10:946.
Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the WHO 2008 classification system. Blood. 2009;13:1906.
Larson RA, Le Beau MM. Therapy related myeloid leukemia: a model for leukomogenesis in humans. Chem Biol Interact. 2005;153:187.
Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplatic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer. 2002;33:331.
Smith SM, Le Beau MM, Hou D. Clinical cytogenetic associations in 306 patients with therapy related myelodysplasia and myeloid leukemia: the university of Chicago series. Blood. 2003;102:43.
Michels SD, McKenna RW, Arthur DC, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65:1364.
Secker-Walker LM, Moorman AV, Bain BJ, et al. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia. 1998;12:840.
Arber DA. Realistic pathologic classification of acute myeloid leukemia. Am J Clin Pethol. 2001;15:552.
Matsuo T, Cox C, Bennett JM. Prognostic significance of myeloperoxidase positivity of blast cells in acute myeloid leukemia without maturation (FAB M1). Hematol Pathol. 1989;3:153.
Lepelley P, Preudhomme C, Sartaux C, et al. Immunologic detection of myeloperoxidase in poorly differentiated acute leukemia. Eur J Haematol. 1993;50:155.
Loeffler H. Morphologic basis for the MIC classification in acute myeloid leukemia. Recent Results Cancer Res. 1993;131:339.
Catovsky D, Matutes E, Buccheri V, et al. Classification of acute leukemia for the 1990s. Ann Hematol. 1991;62:16.
Ferraris AM, Broccia G, Meloni T, et al. Clonal origin of cells restricted to monocytic differentiation in acute nonlymphocytic leukemia. Blood. 1984;64:817.
Garand R, Duchayne E, Blanchard D, Robillard N, et al. Minimally differentiated erythroleukaemia(AML M6 ‘variant’): a rare subset of AML distinct from AML M6. Groupe Francais d’Hematologie Cellulaire. Br J Haematol. 1995;90:868.
Bearman RM, Pangalis GA, Rappaport H. Acute (malignant) myelosclerosis. Cancer. 1979;43:279.
Sultan C, Sigaux F, Imbert M, Reyes F. Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol. 1981;49:11.
Thiele J, Kvasnicka HM, Zerhusen G, et al. Acute pan myelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up. Ann Hematol. 2004;83:513.
Orazi A, O’Malley DP, Jiang J, et al. Acute pan myelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol. 2005;18:603.
Muss HB, Moleney WC. Chloroma and other myeloblastic tumors. Blood. 1973;42:721.
Pileri SA, Asacni S, Cox MC, et al. Myeloid sarcoma: clinicopathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21:340.
Greene ME, Mundschau G, Wechsler J, et al. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003;31:351.
Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399.
Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606.
Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its reletionship to dendritic cells. Am J Clin Pathol. 2007;127:687.
Herling M, Teitell MA, Shen PR, et al. TCL1 expression in plasmacytoid dendritic cells (DC2c) and the related CD4+, CD56+ blastic tumors of skin. Blood. 2003;101:5007.
Pilicowska ME, Fleming MD, Pinkus JL, Pinkus GS. CD4+/CD56+ hematodermicneoplasm (blastic natural killer lymphoma): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol. 2007;128:445.
Khoury JD, Medeiros LJ, Manning JT, et al. CD56+, TdT+ blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer. 2002;94:2401.
Campana D, Hansen-Hagge TE, Matutes E, et al. Phenotypic, genotypic, cytochemical, and ultrastructural characterization of acute undifferentiated leukemia. Leukemia. 1990;4:620.
Brito-Babapulle F, Pullon H, Layton DM, et al. Clinicopathological features of acute undifferentiated leukaemia with a stem cell phenotype. Br J Haematol. 1990;76:210.
Chaperot L, Bendriss N, Manches O, et al. İdentification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97:3210.
Inati A, Salon SE, Cassadi JR, et al. Efficiacy and morbidity of central nervous system prophylaxis in children acute lymphoblastic leukemia: eight years experience with cranial irradiation and intrathecal methotrexate. Blood. 1983;61:297.
Thomas LB. Pathology of leukemia in the brain and meninges: postmortem studies of patients with acute and of mice given L1210 leukemia. Cancer Res. 1965;25:155.
Cassileth PA, Sylvester LS, Bennett JM, Begg CB. High peripheral blast count in acute myelogeneous leukemia is a primary risk factor for CNS leukemia. J Clin Oncol. 1988;6:495.
Mastrangelo R, Roplack D, Bleyer A, et al. Report on recommendations of the Rome Workshop concerning poor prognosis acute lymphoblastic leukemia in children: biologic basis for staging, stratification and treatment. Med Pediatr Oncol. 1986;14:191.
Anastasi J, Freg J, Le Beau MM, et al. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescent insitu hybridization: lineage, response to growth factor therapy and clone expression. Blood. 1993;81:1580.
Raskind WH, Tirumali N, Jacobson R, et al. Evidence for a multistep pathogenesis of myelodysplastic syndrome. Blood. 1984;63:1318.
Jansen JWG, Bushle M, Drexler HG, et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood. 1984;73:248.
Turhan AG, Humpheries RK, Phillips GL, et al. Clonal hematopoiesis demonstratred by X-linked DNA polymorphism after allogeneic bone marrow transplantation. N Engl J Med. 1989;320:1655.
Haase D, Fonatsch C, Freund M, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol. 1995;70:171.
Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986;4:325.
Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia. 1993;7:499.
Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features intreatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia. 2002;16:2366.
Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol. 2005;32:3.
Valent P, Horny HP, Bennett JM, et al. Definitions and standarts in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:227.
Bennett JM. The classification and management of the myelodysplastic syndromes: areas of controversy. Hematol Rev. 1993;7:189.
Goasguen JE, Bennett JM. Classification and morphologic features of myelodysplastic syndromes. Semin Oncol. 1992;19:4.
Kouides PA, Bennett JM. Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin N Am. 1992;6:485.
Rios A, Canizo MC, Sanz MA, et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol. 1990;75:26.
Tuzuner N, Bennett JM. Reference standards for bone marrow cellularity. Leuk Res. 1994;18:645.
Tuzuner N, Cox C, Rowe JM, Bennett JM. Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. Leuk Res. 1994;18:559.
Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol. 1984;58:217.
Horny HP, Greschniok A, Jordan JH, Menke DM, Valent P. Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study. J Clin Pathol. 2003;56:103.
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of myelodysplastic syndrome. Br J Haematol. 1982;51:189.
Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 92–3.
Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Hematologica. 2006;91:1596.
Grasso JA, Myer TJ, Hines JD, Sullivan AL. Energy-dispersive X-ray analysis of the mitochondria of sideroblastic anemia. Br J Haematol. 1980;46:57.
Juneja SK, Impert M, Sigaux F, et al. Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. J Clin Pathol. 1983;36:566.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079.
Germing U, Strupp C, Kuendgen A, et al. Refractory anemia with excess blasts (RAEB): analysis and reclassification to the WHO proposals. Br J Haematol. 2006;132:162.
Lambertenghi-Deliliers G, Orazi A, Luksch R, et al. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol. 1991;78:161.
Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol. 1992;48:208.
Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD 34 positive cell clusters in primary myelodysplastic syndrome. J Clin Oncol. 2009;27:754.
Thide T, Engquist L, Billstrom R. Application of megakaryocyte morphology in diagnosis of –5q syndrome. Eur J Hematol. 1988;41:434.
Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18:113.
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456.
Bauman I, Niemeyer CM, Bennett JM, Shannon K. Childhood myelodysplastic syndrome. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 104–7.
Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood. 2003;102:1997.
Tuzuner N, Cox C, Rowe JM, Bennett JM. Hypocellular acute myeloid leukemia: the Rochester (New York) experience. Hematol Pathol. 1995;9:195.
Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndrome: new proposals. Br J Haematol. 1995;91:612.
Bennet JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recomendations for a standardized approach. Hematologica. 2009;94:264.
Yue G, Hao S, Fadare O, et al. Hypocellularity in myelodysplastic syndrome is an independent factorwhich predicts a favorable outcome. Leuk Res. 2008;32:553.
Fohlmeister I, Fischer R, Mödder B, et al. Aplastic anemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic and prognostic features. J Clin Pathol. 1985;38:1218.
Orazi A, Albitar M, Heerema NA, et al. Hypocellular myelodtsplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol. 1997;107:268.
Orazi A, Bennett JM, Germing U, et al. Chronic myelomonocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 76–79.
Germing U, Strupp C, Knipp S, et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. Hematologica. 2007;92:974.
Storniolo AM, Moleney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4:766.
Kurzock R, Bueso-Ramos CE, Kantajian H, et al. BCR rearrangement negative chronic myelogeneos leukemia revisited. J Clin Oncol. 2001;19:2915.
Baumann I, Bennett JM, Niemeyer CM, Thiele J, Shannon K. Juvenile myelomonocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 82.
Neimeyer CM, Arico M, Basso B, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes of Childhood (EWOG-MDS). Blood. 1997;89:3534.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tuzuner, N.N., Bennett, J.M. (2013). Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. In: Wiernik, P., Goldman, J., Dutcher, J., Kyle, R. (eds) Neoplastic Diseases of the Blood. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3764-2_16
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3764-2_16
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3763-5
Online ISBN: 978-1-4614-3764-2
eBook Packages: MedicineMedicine (R0)